UNSPSC 51182206: Atosiban

This classification denotes a hormone antagonist with the molecular formula C43H67N11O12S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 081D12SI0Z, chemically known as oxytocin, 1-(3-mercaptopropanoic acid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l-ornithine- but generally known as atosiban, which bears US NIH Compound Identifier 68613. European Medicines Agency schedules Atosiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05601MIG.

UNSPSC 51182206 Atosiban, a Commodity code, covers pharmaceutical products supplied through state and local cooperative purchasing arrangements. State and local governments procure atosiban and related pharmaceuticals as part of broader generic multi-source drug programs administered through cooperative purchasing alliances and state pharmacy departments. Issuing bodies include state departments of administration, health agencies, and participating municipalities and counties that source drugs through established cooperative vehicles. The work centers on establishing supply contracts with manufacturers or authorized distributors to deliver pharmaceuticals meeting FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements, with vendors expected to maintain relationships with licensed wholesalers and provide pricing in multiple formats (flat price, net price, WAC-minus).

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The procurement spans participating state and local government facilities across multiple states, including Oregon. MMCAP requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and evaluates proposals on price competitiveness (75 percent), fixed pricing for the contract term (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and data format requirements (5 percent). The contract term is two years for new responders with optional extensions, effective July 1, 2026, and vendors must carry commercial general liability of $5,000,000 per occurrence and maintain comprehensive insurance coverage. Performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials, and vendors pay a 3 percent administrative fee on all contract purchases.